Allogene Therapeutics (ALLO) Stock Forecast, Price & News

Allogene Therapeutics (NASDAQ:ALLO) Frequently Asked Questions

Is Allogene Therapeutics a buy right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Allogene Therapeutics in the last twelve months. There are currently 2 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Allogene Therapeutics stock.
View analyst ratings for Allogene Therapeutics or view top-rated stocks.

When is Allogene Therapeutics' next earnings date?

Allogene Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Allogene Therapeutics.

How were Allogene Therapeutics' earnings last quarter?

Allogene Therapeutics, Inc. (NASDAQ:ALLO) posted its earnings results on Wednesday, May, 4th. The company reported ($0.56) EPS for the quarter, topping analysts' consensus estimates of ($0.58) by $0.02. Allogene Therapeutics had a negative net margin of 148,214.64% and a negative trailing twelve-month return on equity of 32.28%. During the same period in the prior year, the firm posted ($0.25) earnings per share.
View Allogene Therapeutics' earnings history.

What price target have analysts set for ALLO?

13 brokers have issued 1 year price objectives for Allogene Therapeutics' shares. Their forecasts range from $12.00 to $53.00. On average, they anticipate Allogene Therapeutics' share price to reach $30.00 in the next twelve months. This suggests a possible upside of 301.1% from the stock's current price.
View analysts' price targets for Allogene Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Allogene Therapeutics' key executives?

Allogene Therapeutics' management team includes the following people:

• Dr. Arie S. Belldegrun F.A.C.S., FACS, M.D., Co-Founder & Exec. Chairman (Age 73, Pay $845.19k)
• Dr. David D. Chang M.D., Ph.D., Co-Founder, Pres, CEO & Director (Age 62, Pay $1.26M)
• Mr. Joshua A. Kazam, Co-Founder & Director (Age 45, Pay $390k)
• Dr. Eric Thomas Schmidt Ph.D., Chief Financial Officer (Age 52, Pay $660k)
• Dr. Alison Moore Ph.D., Chief Technical Officer (Age 54, Pay $660k)
• Mr. Veer Bhavnagri, Gen. Counsel & Compliance Officer (Age 39, Pay $646.88k) (LinkedIn Profile)
• Dr. Rafael G. Amado, Chief Medical Officer and Exec. VP of R&D (Age 58, Pay $840k) (LinkedIn Profile)
• Ms. Barbra Sasu, Chief Scientific Officer
• Ms. Christine Cassiano, Chief Communications Officer
• Mr. David M. Tanen J.D., Sec. (Age 51)

What is David Chang's approval rating as Allogene Therapeutics' CEO?

2 employees have rated Allogene Therapeutics CEO David Chang on Glassdoor.com. David Chang has an approval rating of 100% among Allogene Therapeutics' employees. This puts David Chang in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Allogene Therapeutics' key competitors?

Some companies that are related to Allogene Therapeutics include Ablynx (ABLYF), Abcam (ABCM), Vir Biotechnology (VIR), Denali Therapeutics (DNLI), Iovance Biotherapeutics (IOVA), Beam Therapeutics (BEAM), Bavarian Nordic A/S (BVNRY), Fate Therapeutics (FATE), Twist Bioscience (TWST), Relay Therapeutics (RLAY), SpringWorks Therapeutics (SWTX), BioCryst Pharmaceuticals (BCRX), ImmunityBio (IBRX), Vaxcyte (PCVX) and Krystal Biotech (KRYS).
View all of ALLO's competitors.

What other stocks do shareholders of Allogene Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allogene Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pfizer (PFE), Teladoc Health (TDOC), AbbVie (ABBV), Alibaba Group (BABA), Bristol-Myers Squibb (BMY) and CRISPR Therapeutics (CRSP).

When did Allogene Therapeutics IPO?

(ALLO) raised $272 million in an IPO on Thursday, October 11th 2018. The company issued 16,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies acted as the underwriters for the IPO.

What is Allogene Therapeutics' stock symbol?

Allogene Therapeutics trades on the NASDAQ under the ticker symbol "ALLO."

Who are Allogene Therapeutics' major shareholders?

Allogene Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include State Street Corp (5.49%), BlackRock Inc. (4.93%), Vanguard Group Inc. (4.70%), Primecap Management Co. CA (3.42%), JPMorgan Chase & Co. (2.48%) and Goldman Sachs Group Inc. (2.06%). Company insiders that own Allogene Therapeutics stock include Alison Moore, Arie Belldegrun, David D Chang, Eric Thomas Schmidt, Group Holdings (Sbs) Advis Tpg, Owen N Witte, Owen N Witte, Rafael Amado and Veer Bhavnagri.
View institutional ownership trends for Allogene Therapeutics.

Which major investors are selling Allogene Therapeutics stock?

ALLO stock was sold by a variety of institutional investors in the last quarter, including Capital International Investors, Citigroup Inc., Duality Advisers LP, Panagora Asset Management Inc., Woodline Partners LP, JPMorgan Chase & Co., Group One Trading L.P., and Maven Securities LTD. Company insiders that have sold Allogene Therapeutics company stock in the last year include Alison Moore, David D Chang, Eric Thomas Schmidt, Owen N Witte, Rafael Amado, and Veer Bhavnagri.
View insider buying and selling activity for Allogene Therapeutics or view top insider-selling stocks.

Which major investors are buying Allogene Therapeutics stock?

ALLO stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Goldman Sachs Group Inc., Renaissance Technologies LLC, BlackRock Inc., Pier Capital LLC, Nordea Investment Management AB, Primecap Management Co. CA, and Graham Capital Management L.P..
View insider buying and selling activity for Allogene Therapeutics or or view top insider-buying stocks.

How do I buy shares of Allogene Therapeutics?

Shares of ALLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Allogene Therapeutics' stock price today?

One share of ALLO stock can currently be purchased for approximately $7.48.

How much money does Allogene Therapeutics make?

Allogene Therapeutics has a market capitalization of $1.07 billion and generates $38.49 million in revenue each year. The company earns $-257.01 million in net income (profit) each year or ($2.200010) on an earnings per share basis.

How many employees does Allogene Therapeutics have?

Allogene Therapeutics employs 308 workers across the globe.

What is Allogene Therapeutics' official website?

The official website for Allogene Therapeutics is www.allogene.com.

How can I contact Allogene Therapeutics?

Allogene Therapeutics' mailing address is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (650) 457-2700 or via email at [email protected].